Endocrine Abstracts

Context: There is growing evidence that cannabinoid receptor-1 (CB-1) blockade reduces inflammation and neovascularization by decreasing vascular endothelial growth factor (VEGF) levels associated with a reduction in inflammatory markers, thereby potentially reducing cardiovascular risk.Objective: To determine the impact of CB1 antagonism by rimonabant on VEGF and inflammatory markers in obese PCOS women.Design: Randomised, open-la...

Background: PCOS is associated with a clustering of cardiovascular risk factors. Increased serum levels of vascular endothelial growth factor (VEGF) are thought to be proatherogenic, and have also been found to be elevated in PCOS. This study was undertaken to determine the changes of VEGF in patients with PCOS after rimonabant and/or metformin intervention.Methods: A 6-month randomised open labelled parallel study of rimonabant or metformin in 20 patien...

Context: Hyperandrogenemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS). In patients with PCOS, testosterone and androstenedione are primarily derived from the ovaries and DHEAS is a metabolite predominantly from the adrenals. It has been shown that atorvastatin reduces testosterone levels in patients with PCOS.Objective:...

Objective: We aim to study whether a difference exists in cardiovascular risk and variability of IR within the hyperandrogenic group of women with PCOS who are ovulatory and anovulatory.Method: Fifty-three women with PCOS were recruited. All subjects were diagnosed to have PCOS by the ESHRE/ASRM Rotterdam criteria where all patients had evidence of biochemical hyperandrogenism and hirsutism, chronic anovulation and polycystic ovaries on transvaginal ultr...

Context: Weight loss and metformin therapy are beneficial in improving the hormonal and metabolic consequences of PCOS. Rimonabant has been found to reduce weight and improve the metabolic profile in patients with metabolic syndrome.Objective: To compare the effects of metformin and rimonabant on insulin resistance and biochemical hyperandrogenemia.Subjects: Twenty patients with PCOS and biochemical hyperandrogenemia were recruited...

Context: Rimonabant has been found to reduce weight and improve the metabolic profile in patients with metabolic syndrome as well as PCOS.Objective: To compare the effects of metformin and rimonabant in patients with PCOS with and without metabolic syndrome according to ATP III criteria.Design: A randomised open labelled parallel study comparing the effects on rimonabant and metformin in patients with PCOS.Su...

Introduction: Polycystic ovary syndrome (PCOS) is associated with known cardiovascular risk factors, consequently predisposing to premature cardiovascular disease. Blood clot structure has been shown to predict predisposition to atherothrombosis and the aim of this study was to investigate the effects of rimonabant and metformin on clot structure/function in women with PCOS.Methods: Twenty women with PCOS were recruited in a randomised open labelled para...

Objective: Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with PCOS compared to metformin. Metformin has also been shown to maintain the weight loss and enhance the metabolic and biochemical parameters achieved by treatment with rimonabant. We have determined the effect of rimonabant on the incretin hormones in patients with PCOS.Design: A randomized open labelled parallel study of metformin...

Introduction: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers.Objective: To assess the effects of 6 months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to matched controls.Design: Interventional case–control study. Carotid intima-media wall thickness (cIMT) was measured by ...

Introduction: Previous studies investigating cardiovascular (CV) risk in obese women with polycystic ovary syndrome (PCOS) have been potentially confounded by not adequately accounting for body weight.Objective: To assess if PCOS increases CV risk independently in young obese women by examining carotid intima-media wall thickness (cIMT) and platelet function.Design: A cross-sectional study comparing women with PCOS (n=21) ...